PMC:7352545 / 45042-46441
Annnotations
LitCovid-PD-FMA-UBERON
{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T385","span":{"begin":131,"end":136},"obj":"Body_part"},{"id":"T386","span":{"begin":346,"end":351},"obj":"Body_part"},{"id":"T387","span":{"begin":393,"end":398},"obj":"Body_part"},{"id":"T388","span":{"begin":405,"end":417},"obj":"Body_part"},{"id":"T389","span":{"begin":477,"end":492},"obj":"Body_part"},{"id":"T390","span":{"begin":562,"end":569},"obj":"Body_part"},{"id":"T391","span":{"begin":582,"end":586},"obj":"Body_part"},{"id":"T392","span":{"begin":587,"end":597},"obj":"Body_part"},{"id":"T393","span":{"begin":637,"end":653},"obj":"Body_part"},{"id":"T394","span":{"begin":648,"end":653},"obj":"Body_part"},{"id":"T395","span":{"begin":668,"end":672},"obj":"Body_part"},{"id":"T396","span":{"begin":673,"end":698},"obj":"Body_part"},{"id":"T397","span":{"begin":693,"end":698},"obj":"Body_part"},{"id":"T398","span":{"begin":942,"end":952},"obj":"Body_part"},{"id":"T399","span":{"begin":1007,"end":1017},"obj":"Body_part"},{"id":"T400","span":{"begin":1269,"end":1280},"obj":"Body_part"},{"id":"T401","span":{"begin":1296,"end":1300},"obj":"Body_part"},{"id":"T402","span":{"begin":1315,"end":1325},"obj":"Body_part"}],"attributes":[{"id":"A385","pred":"fma_id","subj":"T385","obj":"http://purl.org/sig/ont/fma/fma68646"},{"id":"A386","pred":"fma_id","subj":"T386","obj":"http://purl.org/sig/ont/fma/fma68877"},{"id":"A387","pred":"fma_id","subj":"T387","obj":"http://purl.org/sig/ont/fma/fma68646"},{"id":"A388","pred":"fma_id","subj":"T388","obj":"http://purl.org/sig/ont/fma/fma62925"},{"id":"A389","pred":"fma_id","subj":"T389","obj":"http://purl.org/sig/ont/fma/fma63841"},{"id":"A390","pred":"fma_id","subj":"T390","obj":"http://purl.org/sig/ont/fma/fma9637"},{"id":"A391","pred":"fma_id","subj":"T391","obj":"http://purl.org/sig/ont/fma/fma7195"},{"id":"A392","pred":"fma_id","subj":"T392","obj":"http://purl.org/sig/ont/fma/fma9639"},{"id":"A393","pred":"fma_id","subj":"T393","obj":"http://purl.org/sig/ont/fma/fma66768"},{"id":"A394","pred":"fma_id","subj":"T394","obj":"http://purl.org/sig/ont/fma/fma68646"},{"id":"A395","pred":"fma_id","subj":"T395","obj":"http://purl.org/sig/ont/fma/fma7195"},{"id":"A396","pred":"fma_id","subj":"T396","obj":"http://purl.org/sig/ont/fma/fma62499"},{"id":"A397","pred":"fma_id","subj":"T397","obj":"http://purl.org/sig/ont/fma/fma68646"},{"id":"A398","pred":"fma_id","subj":"T398","obj":"http://purl.org/sig/ont/fma/fma82739"},{"id":"A399","pred":"fma_id","subj":"T399","obj":"http://purl.org/sig/ont/fma/fma82739"},{"id":"A400","pred":"fma_id","subj":"T400","obj":"http://purl.org/sig/ont/fma/fma66835"},{"id":"A401","pred":"fma_id","subj":"T401","obj":"http://purl.org/sig/ont/fma/fma74402"},{"id":"A402","pred":"fma_id","subj":"T402","obj":"http://purl.org/sig/ont/fma/fma67093"}],"text":"SARS-CoV-2 needs ACE2 for entry. Host proteases such as human ACE2 help viral entry through removement of a barrier to enter human cells through unknown receptors. Human ACE2 is known for its role as the SARS-CoV-2 entry receptor and the SARS-CoV receptor. The enzyme ACE-2 in the renin-angiotensin system (RAS) is associated with CoV entry into lungs. ACE2 mediates SARS-2002 entry into host cells via S glycoprotein interaction with the ACE2 receptor. The ACE2 levels on the plasma membrane correlate with virus infectivity. ACE2 expression is present in most tissues such as the lung epithelium. It is highly expressed by respiratory epithelial cells and type I/II lung alveolar epithelial cells [88]. The host receptor is not linked to the classification of CoVs. MERS-CoV, a β-CoV, does not recognize the ACE2 receptor. In contrast, the α-CoV HCoV-NL63 recognizes the ACE2 receptor. ACE2 is a membrane-anchored carboxypeptidase with 805 amino acid residues and is captopril-insensitive. It contains 17 amino acid residues as a signal peptide in the N-terminal region, a type I membrane-anchored domain in the C-terminal region, an extracellular N-terminal domain with heavy N-glycans, a N-terminal SARS-CoV-binding and carboxypeptidase site and a short C-terminal cytoplasmic tail. The ACE2 gene is located on chromosome Xp22. Two ACE2 forms are known, a membrane-bound form and a soluble form."}
LitCovid-PD-UBERON
{"project":"LitCovid-PD-UBERON","denotations":[{"id":"T13","span":{"begin":281,"end":305},"obj":"Body_part"},{"id":"T14","span":{"begin":307,"end":310},"obj":"Body_part"},{"id":"T15","span":{"begin":582,"end":597},"obj":"Body_part"},{"id":"T16","span":{"begin":582,"end":586},"obj":"Body_part"},{"id":"T17","span":{"begin":587,"end":597},"obj":"Body_part"},{"id":"T18","span":{"begin":668,"end":672},"obj":"Body_part"},{"id":"T19","span":{"begin":1281,"end":1285},"obj":"Body_part"}],"attributes":[{"id":"A13","pred":"uberon_id","subj":"T13","obj":"http://purl.obolibrary.org/obo/UBERON_0018229"},{"id":"A14","pred":"uberon_id","subj":"T14","obj":"http://purl.obolibrary.org/obo/UBERON_0018229"},{"id":"A15","pred":"uberon_id","subj":"T15","obj":"http://purl.obolibrary.org/obo/UBERON_0000115"},{"id":"A16","pred":"uberon_id","subj":"T16","obj":"http://purl.obolibrary.org/obo/UBERON_0002048"},{"id":"A17","pred":"uberon_id","subj":"T17","obj":"http://purl.obolibrary.org/obo/UBERON_0000483"},{"id":"A18","pred":"uberon_id","subj":"T18","obj":"http://purl.obolibrary.org/obo/UBERON_0002048"},{"id":"A19","pred":"uberon_id","subj":"T19","obj":"http://purl.obolibrary.org/obo/UBERON_0002415"}],"text":"SARS-CoV-2 needs ACE2 for entry. Host proteases such as human ACE2 help viral entry through removement of a barrier to enter human cells through unknown receptors. Human ACE2 is known for its role as the SARS-CoV-2 entry receptor and the SARS-CoV receptor. The enzyme ACE-2 in the renin-angiotensin system (RAS) is associated with CoV entry into lungs. ACE2 mediates SARS-2002 entry into host cells via S glycoprotein interaction with the ACE2 receptor. The ACE2 levels on the plasma membrane correlate with virus infectivity. ACE2 expression is present in most tissues such as the lung epithelium. It is highly expressed by respiratory epithelial cells and type I/II lung alveolar epithelial cells [88]. The host receptor is not linked to the classification of CoVs. MERS-CoV, a β-CoV, does not recognize the ACE2 receptor. In contrast, the α-CoV HCoV-NL63 recognizes the ACE2 receptor. ACE2 is a membrane-anchored carboxypeptidase with 805 amino acid residues and is captopril-insensitive. It contains 17 amino acid residues as a signal peptide in the N-terminal region, a type I membrane-anchored domain in the C-terminal region, an extracellular N-terminal domain with heavy N-glycans, a N-terminal SARS-CoV-binding and carboxypeptidase site and a short C-terminal cytoplasmic tail. The ACE2 gene is located on chromosome Xp22. Two ACE2 forms are known, a membrane-bound form and a soluble form."}
LitCovid-PD-MONDO
{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T153","span":{"begin":0,"end":8},"obj":"Disease"},{"id":"T154","span":{"begin":204,"end":212},"obj":"Disease"},{"id":"T155","span":{"begin":238,"end":246},"obj":"Disease"},{"id":"T156","span":{"begin":367,"end":371},"obj":"Disease"},{"id":"T157","span":{"begin":1203,"end":1211},"obj":"Disease"}],"attributes":[{"id":"A153","pred":"mondo_id","subj":"T153","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A154","pred":"mondo_id","subj":"T154","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A155","pred":"mondo_id","subj":"T155","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A156","pred":"mondo_id","subj":"T156","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A157","pred":"mondo_id","subj":"T157","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"}],"text":"SARS-CoV-2 needs ACE2 for entry. Host proteases such as human ACE2 help viral entry through removement of a barrier to enter human cells through unknown receptors. Human ACE2 is known for its role as the SARS-CoV-2 entry receptor and the SARS-CoV receptor. The enzyme ACE-2 in the renin-angiotensin system (RAS) is associated with CoV entry into lungs. ACE2 mediates SARS-2002 entry into host cells via S glycoprotein interaction with the ACE2 receptor. The ACE2 levels on the plasma membrane correlate with virus infectivity. ACE2 expression is present in most tissues such as the lung epithelium. It is highly expressed by respiratory epithelial cells and type I/II lung alveolar epithelial cells [88]. The host receptor is not linked to the classification of CoVs. MERS-CoV, a β-CoV, does not recognize the ACE2 receptor. In contrast, the α-CoV HCoV-NL63 recognizes the ACE2 receptor. ACE2 is a membrane-anchored carboxypeptidase with 805 amino acid residues and is captopril-insensitive. It contains 17 amino acid residues as a signal peptide in the N-terminal region, a type I membrane-anchored domain in the C-terminal region, an extracellular N-terminal domain with heavy N-glycans, a N-terminal SARS-CoV-binding and carboxypeptidase site and a short C-terminal cytoplasmic tail. The ACE2 gene is located on chromosome Xp22. Two ACE2 forms are known, a membrane-bound form and a soluble form."}
LitCovid-PD-CLO
{"project":"LitCovid-PD-CLO","denotations":[{"id":"T603","span":{"begin":56,"end":61},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_9606"},{"id":"T604","span":{"begin":106,"end":107},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T605","span":{"begin":125,"end":136},"obj":"http://purl.obolibrary.org/obo/CLO_0053065"},{"id":"T606","span":{"begin":164,"end":169},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_9606"},{"id":"T607","span":{"begin":346,"end":351},"obj":"http://www.ebi.ac.uk/efo/EFO_0000934"},{"id":"T608","span":{"begin":393,"end":398},"obj":"http://purl.obolibrary.org/obo/GO_0005623"},{"id":"T609","span":{"begin":477,"end":483},"obj":"http://purl.obolibrary.org/obo/UBERON_0001969"},{"id":"T610","span":{"begin":484,"end":492},"obj":"http://purl.obolibrary.org/obo/UBERON_0000158"},{"id":"T611","span":{"begin":508,"end":513},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_10239"},{"id":"T612","span":{"begin":582,"end":597},"obj":"http://purl.obolibrary.org/obo/UBERON_0000115"},{"id":"T613","span":{"begin":637,"end":647},"obj":"http://purl.obolibrary.org/obo/CL_0000066"},{"id":"T614","span":{"begin":648,"end":662},"obj":"http://purl.obolibrary.org/obo/CL_0000000"},{"id":"T615","span":{"begin":668,"end":672},"obj":"http://purl.obolibrary.org/obo/UBERON_0002048"},{"id":"T616","span":{"begin":668,"end":672},"obj":"http://www.ebi.ac.uk/efo/EFO_0000934"},{"id":"T617","span":{"begin":682,"end":692},"obj":"http://purl.obolibrary.org/obo/CL_0000066"},{"id":"T618","span":{"begin":693,"end":698},"obj":"http://purl.obolibrary.org/obo/GO_0005623"},{"id":"T619","span":{"begin":778,"end":779},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T620","span":{"begin":896,"end":897},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T621","span":{"begin":898,"end":906},"obj":"http://purl.obolibrary.org/obo/UBERON_0000158"},{"id":"T622","span":{"begin":942,"end":961},"obj":"http://purl.obolibrary.org/obo/CHEBI_33708"},{"id":"T623","span":{"begin":942,"end":961},"obj":"http://purl.obolibrary.org/obo/PR_000036907"},{"id":"T624","span":{"begin":1007,"end":1026},"obj":"http://purl.obolibrary.org/obo/CHEBI_33708"},{"id":"T625","span":{"begin":1007,"end":1026},"obj":"http://purl.obolibrary.org/obo/PR_000036907"},{"id":"T626","span":{"begin":1030,"end":1031},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T627","span":{"begin":1032,"end":1038},"obj":"http://purl.obolibrary.org/obo/SO_0000418"},{"id":"T628","span":{"begin":1039,"end":1046},"obj":"http://purl.obolibrary.org/obo/PR_000018263"},{"id":"T629","span":{"begin":1073,"end":1074},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T630","span":{"begin":1082,"end":1090},"obj":"http://purl.obolibrary.org/obo/UBERON_0000158"},{"id":"T631","span":{"begin":1190,"end":1191},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T632","span":{"begin":1250,"end":1251},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T633","span":{"begin":1281,"end":1285},"obj":"http://purl.obolibrary.org/obo/UBERON_0002415"},{"id":"T634","span":{"begin":1296,"end":1300},"obj":"http://purl.obolibrary.org/obo/OGG_0000000002"},{"id":"T635","span":{"begin":1358,"end":1359},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T636","span":{"begin":1360,"end":1368},"obj":"http://purl.obolibrary.org/obo/UBERON_0000158"},{"id":"T637","span":{"begin":1384,"end":1385},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"}],"text":"SARS-CoV-2 needs ACE2 for entry. Host proteases such as human ACE2 help viral entry through removement of a barrier to enter human cells through unknown receptors. Human ACE2 is known for its role as the SARS-CoV-2 entry receptor and the SARS-CoV receptor. The enzyme ACE-2 in the renin-angiotensin system (RAS) is associated with CoV entry into lungs. ACE2 mediates SARS-2002 entry into host cells via S glycoprotein interaction with the ACE2 receptor. The ACE2 levels on the plasma membrane correlate with virus infectivity. ACE2 expression is present in most tissues such as the lung epithelium. It is highly expressed by respiratory epithelial cells and type I/II lung alveolar epithelial cells [88]. The host receptor is not linked to the classification of CoVs. MERS-CoV, a β-CoV, does not recognize the ACE2 receptor. In contrast, the α-CoV HCoV-NL63 recognizes the ACE2 receptor. ACE2 is a membrane-anchored carboxypeptidase with 805 amino acid residues and is captopril-insensitive. It contains 17 amino acid residues as a signal peptide in the N-terminal region, a type I membrane-anchored domain in the C-terminal region, an extracellular N-terminal domain with heavy N-glycans, a N-terminal SARS-CoV-binding and carboxypeptidase site and a short C-terminal cytoplasmic tail. The ACE2 gene is located on chromosome Xp22. Two ACE2 forms are known, a membrane-bound form and a soluble form."}
LitCovid-PD-CHEBI
{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T1432","span":{"begin":287,"end":298},"obj":"Chemical"},{"id":"T1433","span":{"begin":307,"end":310},"obj":"Chemical"},{"id":"T1434","span":{"begin":405,"end":417},"obj":"Chemical"},{"id":"T1435","span":{"begin":665,"end":667},"obj":"Chemical"},{"id":"T1436","span":{"begin":942,"end":952},"obj":"Chemical"},{"id":"T1437","span":{"begin":942,"end":947},"obj":"Chemical"},{"id":"T1438","span":{"begin":948,"end":952},"obj":"Chemical"},{"id":"T1439","span":{"begin":969,"end":978},"obj":"Chemical"},{"id":"T1440","span":{"begin":1007,"end":1017},"obj":"Chemical"},{"id":"T1441","span":{"begin":1007,"end":1012},"obj":"Chemical"},{"id":"T1442","span":{"begin":1013,"end":1017},"obj":"Chemical"},{"id":"T1443","span":{"begin":1039,"end":1046},"obj":"Chemical"},{"id":"T1444","span":{"begin":1179,"end":1188},"obj":"Chemical"},{"id":"T1445","span":{"begin":1181,"end":1188},"obj":"Chemical"}],"attributes":[{"id":"A1432","pred":"chebi_id","subj":"T1432","obj":"http://purl.obolibrary.org/obo/CHEBI_48433"},{"id":"A1433","pred":"chebi_id","subj":"T1433","obj":"http://purl.obolibrary.org/obo/CHEBI_63620"},{"id":"A1434","pred":"chebi_id","subj":"T1434","obj":"http://purl.obolibrary.org/obo/CHEBI_17089"},{"id":"A1435","pred":"chebi_id","subj":"T1435","obj":"http://purl.obolibrary.org/obo/CHEBI_74067"},{"id":"A1436","pred":"chebi_id","subj":"T1436","obj":"http://purl.obolibrary.org/obo/CHEBI_33709"},{"id":"A1437","pred":"chebi_id","subj":"T1437","obj":"http://purl.obolibrary.org/obo/CHEBI_46882"},{"id":"A1438","pred":"chebi_id","subj":"T1438","obj":"http://purl.obolibrary.org/obo/CHEBI_37527"},{"id":"A1439","pred":"chebi_id","subj":"T1439","obj":"http://purl.obolibrary.org/obo/CHEBI_3380"},{"id":"A1440","pred":"chebi_id","subj":"T1440","obj":"http://purl.obolibrary.org/obo/CHEBI_33709"},{"id":"A1441","pred":"chebi_id","subj":"T1441","obj":"http://purl.obolibrary.org/obo/CHEBI_46882"},{"id":"A1442","pred":"chebi_id","subj":"T1442","obj":"http://purl.obolibrary.org/obo/CHEBI_37527"},{"id":"A1443","pred":"chebi_id","subj":"T1443","obj":"http://purl.obolibrary.org/obo/CHEBI_16670"},{"id":"A1444","pred":"chebi_id","subj":"T1444","obj":"http://purl.obolibrary.org/obo/CHEBI_59520"},{"id":"A1445","pred":"chebi_id","subj":"T1445","obj":"http://purl.obolibrary.org/obo/CHEBI_18154"}],"text":"SARS-CoV-2 needs ACE2 for entry. Host proteases such as human ACE2 help viral entry through removement of a barrier to enter human cells through unknown receptors. Human ACE2 is known for its role as the SARS-CoV-2 entry receptor and the SARS-CoV receptor. The enzyme ACE-2 in the renin-angiotensin system (RAS) is associated with CoV entry into lungs. ACE2 mediates SARS-2002 entry into host cells via S glycoprotein interaction with the ACE2 receptor. The ACE2 levels on the plasma membrane correlate with virus infectivity. ACE2 expression is present in most tissues such as the lung epithelium. It is highly expressed by respiratory epithelial cells and type I/II lung alveolar epithelial cells [88]. The host receptor is not linked to the classification of CoVs. MERS-CoV, a β-CoV, does not recognize the ACE2 receptor. In contrast, the α-CoV HCoV-NL63 recognizes the ACE2 receptor. ACE2 is a membrane-anchored carboxypeptidase with 805 amino acid residues and is captopril-insensitive. It contains 17 amino acid residues as a signal peptide in the N-terminal region, a type I membrane-anchored domain in the C-terminal region, an extracellular N-terminal domain with heavy N-glycans, a N-terminal SARS-CoV-binding and carboxypeptidase site and a short C-terminal cytoplasmic tail. The ACE2 gene is located on chromosome Xp22. Two ACE2 forms are known, a membrane-bound form and a soluble form."}
LitCovid-PD-GO-BP
{"project":"LitCovid-PD-GO-BP","denotations":[{"id":"T71","span":{"begin":377,"end":392},"obj":"http://purl.obolibrary.org/obo/GO_0044409"}],"text":"SARS-CoV-2 needs ACE2 for entry. Host proteases such as human ACE2 help viral entry through removement of a barrier to enter human cells through unknown receptors. Human ACE2 is known for its role as the SARS-CoV-2 entry receptor and the SARS-CoV receptor. The enzyme ACE-2 in the renin-angiotensin system (RAS) is associated with CoV entry into lungs. ACE2 mediates SARS-2002 entry into host cells via S glycoprotein interaction with the ACE2 receptor. The ACE2 levels on the plasma membrane correlate with virus infectivity. ACE2 expression is present in most tissues such as the lung epithelium. It is highly expressed by respiratory epithelial cells and type I/II lung alveolar epithelial cells [88]. The host receptor is not linked to the classification of CoVs. MERS-CoV, a β-CoV, does not recognize the ACE2 receptor. In contrast, the α-CoV HCoV-NL63 recognizes the ACE2 receptor. ACE2 is a membrane-anchored carboxypeptidase with 805 amino acid residues and is captopril-insensitive. It contains 17 amino acid residues as a signal peptide in the N-terminal region, a type I membrane-anchored domain in the C-terminal region, an extracellular N-terminal domain with heavy N-glycans, a N-terminal SARS-CoV-binding and carboxypeptidase site and a short C-terminal cytoplasmic tail. The ACE2 gene is located on chromosome Xp22. Two ACE2 forms are known, a membrane-bound form and a soluble form."}
LitCovid-sentences
{"project":"LitCovid-sentences","denotations":[{"id":"T431","span":{"begin":0,"end":32},"obj":"Sentence"},{"id":"T432","span":{"begin":33,"end":163},"obj":"Sentence"},{"id":"T433","span":{"begin":164,"end":256},"obj":"Sentence"},{"id":"T434","span":{"begin":257,"end":352},"obj":"Sentence"},{"id":"T435","span":{"begin":353,"end":453},"obj":"Sentence"},{"id":"T436","span":{"begin":454,"end":526},"obj":"Sentence"},{"id":"T437","span":{"begin":527,"end":598},"obj":"Sentence"},{"id":"T438","span":{"begin":599,"end":704},"obj":"Sentence"},{"id":"T439","span":{"begin":705,"end":767},"obj":"Sentence"},{"id":"T440","span":{"begin":768,"end":824},"obj":"Sentence"},{"id":"T441","span":{"begin":825,"end":887},"obj":"Sentence"},{"id":"T442","span":{"begin":888,"end":991},"obj":"Sentence"},{"id":"T443","span":{"begin":992,"end":1286},"obj":"Sentence"},{"id":"T444","span":{"begin":1287,"end":1331},"obj":"Sentence"},{"id":"T445","span":{"begin":1332,"end":1399},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"SARS-CoV-2 needs ACE2 for entry. Host proteases such as human ACE2 help viral entry through removement of a barrier to enter human cells through unknown receptors. Human ACE2 is known for its role as the SARS-CoV-2 entry receptor and the SARS-CoV receptor. The enzyme ACE-2 in the renin-angiotensin system (RAS) is associated with CoV entry into lungs. ACE2 mediates SARS-2002 entry into host cells via S glycoprotein interaction with the ACE2 receptor. The ACE2 levels on the plasma membrane correlate with virus infectivity. ACE2 expression is present in most tissues such as the lung epithelium. It is highly expressed by respiratory epithelial cells and type I/II lung alveolar epithelial cells [88]. The host receptor is not linked to the classification of CoVs. MERS-CoV, a β-CoV, does not recognize the ACE2 receptor. In contrast, the α-CoV HCoV-NL63 recognizes the ACE2 receptor. ACE2 is a membrane-anchored carboxypeptidase with 805 amino acid residues and is captopril-insensitive. It contains 17 amino acid residues as a signal peptide in the N-terminal region, a type I membrane-anchored domain in the C-terminal region, an extracellular N-terminal domain with heavy N-glycans, a N-terminal SARS-CoV-binding and carboxypeptidase site and a short C-terminal cytoplasmic tail. The ACE2 gene is located on chromosome Xp22. Two ACE2 forms are known, a membrane-bound form and a soluble form."}
2_test
{"project":"2_test","denotations":[{"id":"32604730-32305506-51944046","span":{"begin":700,"end":702},"obj":"32305506"},{"id":"T75465","span":{"begin":700,"end":702},"obj":"32305506"}],"text":"SARS-CoV-2 needs ACE2 for entry. Host proteases such as human ACE2 help viral entry through removement of a barrier to enter human cells through unknown receptors. Human ACE2 is known for its role as the SARS-CoV-2 entry receptor and the SARS-CoV receptor. The enzyme ACE-2 in the renin-angiotensin system (RAS) is associated with CoV entry into lungs. ACE2 mediates SARS-2002 entry into host cells via S glycoprotein interaction with the ACE2 receptor. The ACE2 levels on the plasma membrane correlate with virus infectivity. ACE2 expression is present in most tissues such as the lung epithelium. It is highly expressed by respiratory epithelial cells and type I/II lung alveolar epithelial cells [88]. The host receptor is not linked to the classification of CoVs. MERS-CoV, a β-CoV, does not recognize the ACE2 receptor. In contrast, the α-CoV HCoV-NL63 recognizes the ACE2 receptor. ACE2 is a membrane-anchored carboxypeptidase with 805 amino acid residues and is captopril-insensitive. It contains 17 amino acid residues as a signal peptide in the N-terminal region, a type I membrane-anchored domain in the C-terminal region, an extracellular N-terminal domain with heavy N-glycans, a N-terminal SARS-CoV-binding and carboxypeptidase site and a short C-terminal cytoplasmic tail. The ACE2 gene is located on chromosome Xp22. Two ACE2 forms are known, a membrane-bound form and a soluble form."}